

Special Issue

West Nile Virus Disease

Message from the Guest Editors

West Nile virus (WNV) is the most common mosquito-borne virus in North America. WNV can enter the central nervous system (CNS) and cause WN neuroinvasive disease (WNND) with less understood long term consequences. An association between the WN infection and myasthenia gravis was recently observed in patients long after they recovered from WNND and no prior history of myasthenia gravis. The exact reason for the long-term lingering symptoms after WNV infection are still not well characterized. Therefore, we would like to encourage submission of articles to this special issue, which will cover recent advances in understanding the mechanisms of WNV invasion/infection and neurodegeneration in the CNS, the cause of WNND and reasons for lingering neurological symptoms. Identification of novel therapeutic drugs/peptides, which can suppress the pathologic phenotype is important, articles on this topic are also welcome.

Guest Editors

Dr. Parminder J.S. Vig

Neurology Research Division, Professor of Neurology and Biochemistry,
Department of Neurology, University of Mississippi Medical Center,
2500 North State Street, Jackson, MS 39216, USA

Prof. Dr. Fengwei Bai

Cell and Molecular Biology Program, University of Southern Mississippi,
Hattiesburg, MS 39406, USA

Deadline for manuscript submissions

closed (31 December 2020)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/37189

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).